Bluebird Bio Inc. (BLUE) Shares Down 3.9%
Shares of Bluebird Bio Inc. (NASDAQ:BLUE) dropped 3.9% during mid-day trading on Wednesday . The company traded as low as $48.53 and last traded at $48.90, with a volume of 514,746 shares traded. The stock had previously closed at $50.87.
BLUE has been the topic of a number of analyst reports. Goldman Sachs Group Inc. reaffirmed a “buy” rating and set a $135.00 target price on shares of Bluebird Bio in a research report on Thursday, August 18th. Maxim Group reaffirmed a “buy” rating and set a $85.00 target price (down from $105.00) on shares of Bluebird Bio in a research report on Thursday, August 4th. Jefferies Group reaffirmed a “positive” rating and set a $80.00 target price on shares of Bluebird Bio in a research report on Thursday, July 14th. BTIG Research reaffirmed a “buy” rating and set a $72.00 target price on shares of Bluebird Bio in a research report on Wednesday, June 29th. Finally, Vetr lowered Bluebird Bio from a “buy” rating to a “hold” rating and set a $44.44 target price on the stock. in a research report on Monday, July 4th. Six analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Bluebird Bio presently has a consensus rating of “Buy” and a consensus price target of $82.50.
The stock has a 50-day moving average of $52.84 and a 200 day moving average of $47.18. The firm’s market capitalization is $1.85 billion.
Bluebird Bio (NASDAQ:BLUE) last posted its quarterly earnings results on Wednesday, August 3rd. The company reported ($1.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.44) by $0.15. During the same quarter in the prior year, the company earned ($1.57) earnings per share. The business earned $1.55 million during the quarter, compared to the consensus estimate of $2.01 million. The business’s quarterly revenue was down 68.6% compared to the same quarter last year. Analysts anticipate that Bluebird Bio Inc. will post ($6.14) EPS for the current year.
In other news, insider David Davidson sold 1,000 shares of the business’s stock in a transaction on Wednesday, June 15th. The shares were sold at an average price of $40.11, for a total transaction of $40,110.00. Following the transaction, the insider now directly owns 10,600 shares in the company, valued at approximately $425,166. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Eric Sullivan sold 2,912 shares of the business’s stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $55.01, for a total transaction of $160,189.12. Following the transaction, the insider now owns 4,456 shares in the company, valued at $245,124.56. The disclosure for this sale can be found here.
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.